🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
19/08/2020 24,59 25,48 24,15 25,16 +2,28% 5,41% 473.200
18/08/2020 24,66 24,87 23,93 24,60 +0,00% 3,81% 418.900
17/08/2020 24,03 25,26 23,31 24,60 +3,45% 8,11% 600.100
14/08/2020 24,11 24,16 22,98 23,78 -2,10% 4,90% 365.800
13/08/2020 24,57 24,93 24,02 24,29 -1,82% 3,70% 344.400
12/08/2020 24,63 25,22 24,15 24,74 +7,61% 4,34% 687.900
11/08/2020 23,19 23,46 21,95 22,99 +0,13% 6,53% 510.600
10/08/2020 21,78 23,78 21,78 22,96 +5,56% 9,18% 912.400
07/08/2020 20,71 21,81 20,70 21,75 +3,67% 5,36% 532.500
06/08/2020 21,12 21,69 20,67 20,98 -1,36% 4,83% 401.000
05/08/2020 21,37 22,16 21,01 21,27 +1,33% 5,38% 310.200
04/08/2020 20,88 21,18 20,36 20,99 -0,33% 3,93% 389.500
03/08/2020 19,86 21,21 19,81 21,06 +7,01% 7,05% 534.000
31/07/2020 21,19 21,26 19,34 19,68 -7,87% 9,06% 590.300
30/07/2020 20,87 21,92 20,87 21,36 +0,95% 5,03% 391.400
29/07/2020 21,48 21,79 20,81 21,16 -1,54% 4,56% 300.500
28/07/2020 22,29 22,34 21,23 21,49 -4,19% 4,98% 361.800
27/07/2020 21,83 22,74 21,63 22,43 +1,26% 5,08% 510.600
24/07/2020 22,54 22,74 22,03 22,15 -3,90% 3,15% 534.100
23/07/2020 23,31 24,00 22,92 23,05 -2,04% 4,63% 320.900
22/07/2020 23,56 23,87 23,20 23,53 +0,60% 2,82% 663.600
21/07/2020 24,60 24,68 23,30 23,39 -5,30% 5,61% 370.300
20/07/2020 24,45 25,14 24,12 24,70 +0,94% 4,17% 290.900
17/07/2020 24,14 25,39 23,11 24,47 +1,37% 9,44% 1.055.500
16/07/2020 23,83 24,57 23,19 24,14 +0,25% 5,79% 534.500
15/07/2020 23,75 24,62 23,06 24,08 +2,95% 6,57% 280.400
14/07/2020 22,85 23,58 22,01 23,39 +3,22% 6,87% 861.900
13/07/2020 24,26 24,44 22,57 22,66 -7,25% 7,71% 562.500
10/07/2020 25,50 26,19 24,25 24,43 -4,08% 7,61% 657.300
09/07/2020 25,38 25,97 24,74 25,47 +0,75% 4,84% 428.600